Results 231 to 240 of about 38,538 (308)

Targeting Tumor Stroma: Current Challenges and Future Directions

open access: yesMedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang   +7 more
wiley   +1 more source

Structural stability of symmetric bispecific antibodies: a case study showing potential compromise near linker regions. [PDF]

open access: yesSci Rep
Ingavat N   +13 more
europepmc   +1 more source

Aptamer‐Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap

open access: yesSmall Science, Volume 6, Issue 5, May 2026.
Aptamer‐functionalized nanocarriers represent a versatile platform for targeted therapy in bone and joint diseases. This review presents five complementary design strategies: free aptamers for soluble targets, bispecific multivalent constructs for enhanced avidity, nanoparticle‐conjugated aptamers for selective tissue accumulation, aptamer‐based ...
Hamdi Al‐Azzani   +5 more
wiley   +1 more source

Recurrent cytokine release syndrome in patients receiving bispecific antibody therapy for multiple myeloma: a case series. [PDF]

open access: yesAnn Hematol
Della Pepa R   +7 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Transcriptional Reinforcement of the HER2–RAS Network in HER2‐Positive Gastric Cancer: The RUNX–SOS1 Axis in Context

open access: yesCancer Science, Volume 117, Issue 5, Page 1235-1243, May 2026.
RUNX‐dependent transcriptional control of SOS1 reinforces HER2–RAS signaling and may attenuate responses to HER2‐targeted therapies in HER2‐positive gastric cancer. ABSTRACT HER2‐positive gastric cancer represents a distinct molecular subtype characterized by chromosomal instability, variable HER2 amplification, and substantial intratumoral ...
Tatsuya Masuda   +3 more
wiley   +1 more source

Elranatamab: Mechanism of Action, Clinical, and Translational Science

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Elranatamab (ELREXFIO) is a humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM). Elranatamab engages CD3 on T cells and B‐cell maturation antigen (BCMA) on myeloma cells to induce T cell–mediated myeloma cell cytolysis.
Mohamed Elmeliegy   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy